ImpediMed (IPD.AX) Stock Price
ImpediMed Price
Over the last 19 years ImpediMed grew revenue by 14.0% annually, reaching 14.61 M AUD. For ImpediMed, the net margin of -170.4% is up versus -188.1% a few years ago.
ImpediMed stock price
ImpediMed business model & stock analysis
Frequently asked questions about ImpediMed
The business model of ImpediMed Ltd focuses on developing and commercializing medical devices for measuring and monitoring fluid status and tissue impedance. ImpediMed specializes in bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) technologies, which are used in various medical fields such as lymphedema, heart failure, and chronic kidney disease. The company's products provide non-invasive measurements to help clinicians assess fluid status and tissue composition, aiding in the early detection and management of various medical conditions. ImpediMed's innovative devices and solutions contribute to improved patient outcomes and cost-effective healthcare interventions.
ImpediMed Ltd is primarily active in the healthcare industry.
The main competitors of ImpediMed Ltd in the market are [competitor names].
ImpediMed Ltd is an Australian-based medical technology company founded in 1999. The company specializes in the development and commercialization of bioimpedance spectroscopy (BIS) devices for non-invasive fluid management. ImpediMed's technology has applications in the areas of lymphedema management, early detection of secondary lymphedema, and monitoring of body composition in clinical and research settings. With a focus on improving patient outcomes, ImpediMed has established a strong reputation in the medical field. As a leading provider of BIS technology, ImpediMed continues to innovate and make advancements in the field of medical diagnostics and patient care.
ImpediMed Ltd, a leading medical technology company, has accomplished several significant milestones throughout its journey. The company successfully developed and commercialized its innovative bioimpedance spectroscopy technology, the L-Dex System. This revolutionary product enables early detection of lymphedema, a condition commonly associated with cancer treatment. ImpediMed also received FDA approval for its product, marking a crucial milestone in expanding its market reach. Furthermore, the company has made notable progress through strategic collaborations with prestigious medical institutions and key partnerships with renowned healthcare organizations. ImpediMed's commitment to advancing patient care, combined with its continuous technological advancements, showcases its substantial achievements in the medical technology industry.
ImpediMed Ltd is primarily present in several countries and regions worldwide. The company has a global presence with a focus on key markets including the United States, Australia, and Europe. ImpediMed operates in the healthcare industry, providing medical devices and solutions for the management and monitoring of lymphedema, heart failure, and body composition. With its innovative technologies and strong market penetration, ImpediMed continues to expand its presence and deliver its products to healthcare professionals and patients worldwide.
ImpediMed Ltd represents values of innovation, integrity, and dedication to improving healthcare outcomes. The company's corporate philosophy focuses on providing advanced and accurate medical devices and solutions for the assessment and monitoring of body composition and fluid status. ImpediMed is committed to delivering products that assist healthcare professionals in making informed decisions for better patient management. With a strong emphasis on research and development, ImpediMed continuously strives to revolutionize the field of bioimpedance spectroscopy, ensuring accurate and non-invasive measurements. By placing a significant emphasis on technological advancements, ImpediMed Ltd aims to transform patient care and improve overall health outcomes.
8 analysts currently rate the ImpediMed stock: 7 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the ImpediMed share trades at 0.00 EUR (0.01 AUD).
The ImpediMed share (IPD.AX) is listed on 2 stock exchanges, including: ASX (IPD.AX).
ImpediMed Ltd is a global company specializing in the development of medical devices and solutions for measuring lymphedema and other fluid accumulation in the body. The company was founded in 1999 and is headquartered in Brisbane, Australia. ImpediMed is divided into two main business segments - ImpediMed and Sozo. ImpediMed specializes in the development of bioimpedance devices, while Sozo specializes in the measurement of body fluids by combining bioimpedance with other technologies such as optical imaging and sonography. Sozo specifically addresses data-driven clinical problems by providing doctors and nurses with an objective, automated method for measuring edema. ImpediMed's bioimpedance technology is mainly used for monitoring edema and other conditions caused by irregular fluid accumulation. The device measures the electrical resistance in the tissue, allowing for an accurate determination of extracellular fluid, intracellular fluid, and body fat percentage. ImpediMed's Sozo system combines bioimpedance with other technologies. It provides accurate measurement of extracellular fluid, which is essential for the diagnosis, monitoring, and therapy management of various diseases, including lymphedema. ImpediMed also offers training on specific diseases for doctors and nursing staff. ImpediMed specializes in developing medical products for the field of oncology and lymphedema patients. The company also offers specialized post-care for oncology patients by supporting monitoring for edema, swelling, and body fluids. ImpediMed has established itself as a leading provider of edema monitoring solutions and operates in Europe, Asia, North America, and Australia. The company is committed to providing its customers with reliable and accurate diagnoses to enable a good quality of life for people suffering from various edema conditions. It collaborates with specialized physicians in various medical fields. Overall, ImpediMed is a successful company that has found a niche in the medical industry with its bioimpedance technology. The variety of products and solutions it offers, along with collaborations with specialized physicians, have contributed to its establishment as a leading player in edema monitoring in a short period of time.
The revenue of ImpediMed is 14.61 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of ImpediMed is -24.91 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ImpediMed is currently -0.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ImpediMed stock.
The price-to-sales ratio (P/S) of ImpediMed is currently 0.92. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ImpediMed stock.
The Eulerpool Quality Score for ImpediMed is 4/10.
The ISIN of ImpediMed is AU000000IPD8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of ImpediMed is IPD.AX. The ticker symbol is used to trade ImpediMed shares on the stock exchange.
ImpediMed stock
ImpediMed Peer Group
ImpediMed Ticker
ImpediMed FIGI
All fundamentals and in-depth analysis of ImpediMed
Our stock analysis for ImpediMed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.